デフォルト表紙
市場調査レポート
商品コード
1585794

脳腫瘍診断薬市場:検査タイプ別、脳腫瘍タイプ別、エンドユーザー別-2025-2030年の世界予測

Brain Cancer Diagnostics Market by Test Type (Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, PET Scan), Brain Cancer Type (Acoustic Neuroma, Astrocytomas, Chordomas), End-User - Global Forecast 2025-2030


出版日
発行
360iResearch
ページ情報
英文 183 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.32円
脳腫瘍診断薬市場:検査タイプ別、脳腫瘍タイプ別、エンドユーザー別-2025-2030年の世界予測
出版日: 2024年10月31日
発行: 360iResearch
ページ情報: 英文 183 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

脳腫瘍診断薬市場は、2023年に40億2,000万米ドルと評価され、2024年には45億2,000万米ドルに達すると予測され、CAGR 12.44%で成長し、2030年には91億4,000万米ドルに達すると予測されています。

脳腫瘍診断薬市場の範囲には、画像診断技術(MRI、CTスキャン)、生検、組織学的評価、リキッドバイオプシーや次世代シーケンシングなどの新たな分子診断ツールなど、幅広い技術や手法が含まれます。これらの診断は、早期発見、最も効果的な治療戦略の決定、疾患の進行や再発のモニタリングに極めて重要です。その用途は、病院内の検査室からがん専門センターまで多岐にわたり、エンドユーザーには、がん専門医、神経外科医、病理医などが含まれ、精密医療のためにこれらのツールに依存しています。脳腫瘍の発生率の上昇と診断技術の進歩が市場成長の原動力となっています。さらに、個別化医療や標的治療に対する意識の高まりは、新規診断アプローチを開発する企業にとって大きな市場機会を浮き彫りにしています。

主な市場の統計
基準年[2023] 40億2,000万米ドル
予測年[2024] 45億2,000万米ドル
予測年[2030] 91億4,000万米ドル
CAGR(%) 12.44%

主な成長要因には、画像診断やゲノムプロファイリングにおけるAIや機械学習などの技術進歩が含まれ、診断精度と効率の向上につながります。しかし、市場は先進的な診断ツールに関連する高コスト、診断精度のばらつき、新興国地域でのアクセス制限などの課題に直面しています。規制上のハードルや、複雑な診断データを解釈する熟練者の必要性が、さらに成長を阻害しています。遠隔医療や遠隔診断機能の拡大には潜在的なビジネスチャンスが存在し、世界的に高品質な診断へのアクセスを民主化できる可能性があります。さらに、バイオテクノロジー企業と学術機関との提携は、革新的な診断ツールの研究開発を加速させる可能性があります。

血液を用いた検査や、より高い感度と特異性を持つ画像診断技術の改良など、非侵襲的診断法の革新は、研究と市場成長のための有望な分野です。データ共有を合理化し、診断ツールを包括的なケア・パスに統合するために、ヘルスケア・エコシステム全体で協力体制を育成することは、極めて重要な前進です。固有の課題はあるもの、脳腫瘍診断薬市場は、技術革新と臨床転帰の改善への絶え間ない探求によって、より統合された患者中心のアプローチへと進化しつつあります。企業は、AIと個別化医療のトレンドを活用して競争力を維持し、このダイナミックな分野における将来の成長を促進すべきです。

市場力学:急速に進化する脳腫瘍診断薬市場の主要市場インサイトを公開

脳腫瘍診断薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

  • 市場促進要因
    • 脳腫瘍罹患率の増加
    • 民間診断センター数の増加と官民連携の高まり
  • 市場抑制要因
    • 診断にかかるコストの高さ、診断に関する認知度の低さ
  • 市場機会
    • 診断機器の技術的進歩
    • 様々ながん変異に対する診断アプローチの開発
  • 市場の課題
    • 高い放射線被曝リスクと厳しい規制ガイドラインの増加

ポーターの5つの力:脳腫瘍診断薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析:脳腫瘍診断薬市場における外部からの影響の把握

外部マクロ環境要因は、脳腫瘍診断薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析脳腫瘍診断薬市場における競合情勢の把握

脳腫瘍診断薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス脳腫瘍診断薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、脳腫瘍診断薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨脳腫瘍診断薬市場における成功への道筋を描く

脳腫瘍診断薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています:

1.市場の浸透度:現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度:新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化:最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報:競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション:将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています:

1.現在の市場規模と今後の成長予測は?

2.最高の投資機会を提供する製品、セグメント、地域はどこか?

3.市場を形成する主な技術動向と規制の影響とは?

4.主要ベンダーの市場シェアと競合ポジションは?

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 脳腫瘍の発生率増加
      • 民間診断センター数の増加と官民連携の拡大
    • 抑制要因
      • 診断にかかる高額な費用と診断に関する認知度の低さ
    • 機会
      • 診断機器の技術的進歩
      • さまざまながん変異に対する診断アプローチの開発
    • 課題
      • 高放射線被曝のリスクの高まりと厳しい規制ガイドライン
  • 市場セグメンテーション分析
  • ポーターのファイブフォース分析
  • PESTEL分析
    • 政治的
    • 経済
    • 社交
    • 技術的
    • 法律上
    • 環境

第6章 脳腫瘍診断薬市場テストタイプ別

  • 磁気共鳴画像
  • 磁気共鳴分光法
  • PETスキャン
  • 脊髄穿刺

第7章 脳腫瘍診断薬市場脳腫瘍の種類別

  • 聴神経腫瘍
  • 星細胞腫
  • 脊索腫
  • 上衣腫

第8章 脳腫瘍診断薬市場:エンドユーザー別

  • 診断センター
  • 病院・クリニック

第9章 南北アメリカの脳腫瘍診断薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の脳腫瘍診断薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの脳腫瘍診断薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
  • 戦略分析と提言

企業一覧

  • Abbott Laboratories
  • Associated Regional and University Pathologists, Inc.
  • Becton, Dickinson and Company
  • Bristol Myers Squibb Co.
  • F. Hoffmann-La Roche AG by Roche Holding AG
  • Fujifilm Holdings Corporation
  • GE Healthcare
  • Grail, LLC
  • Henry Ford Health
  • Hitachi, Ltd.
  • Hologic, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • Koninklijke Philips N.V.
  • Laboratory Corporation of America Holdings
  • NantOmics
  • NeoGenomics Laboratories, Inc.
  • Novocure GmbH
  • Oncologica Limited
  • Quibim, S.L.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
図表

LIST OF FIGURES

  • FIGURE 1. BRAIN CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BRAIN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BRAIN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRAIN CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRAIN CANCER DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE SPECTROSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SPINAL TAP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CHORDOMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EPENDYMOMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. BRAIN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. BRAIN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
目次
Product Code: MRR-A26E0E57412A

The Brain Cancer Diagnostics Market was valued at USD 4.02 billion in 2023, expected to reach USD 4.52 billion in 2024, and is projected to grow at a CAGR of 12.44%, to USD 9.14 billion by 2030.

The scope of the brain cancer diagnostics market encompasses a broad range of technologies and methods, including imaging techniques (MRI, CT scans), biopsy and histological assessments, and emerging molecular diagnostic tools such as liquid biopsies and next-generation sequencing. These diagnostics are crucial for early detection, determining the most effective therapeutic strategies, and monitoring disease progression or recurrence. Applications span from hospital-based laboratories to specialized oncology centers, with end-users including oncologists, neurosurgeons, and pathologists who rely on these tools for precision medicine. The rising incidence of brain tumors, coupled with advancements in diagnostics technologies, drives market growth. Additionally, increased awareness of personalized medicine and targeted therapies highlights significant market opportunities for companies developing novel diagnostic approaches.

KEY MARKET STATISTICS
Base Year [2023] USD 4.02 billion
Estimated Year [2024] USD 4.52 billion
Forecast Year [2030] USD 9.14 billion
CAGR (%) 12.44%

Key growth factors include technological advancements, such as AI and machine learning in imaging and genomic profiling, leading to enhanced diagnostic accuracy and efficiency. However, the market faces challenges including high costs associated with advanced diagnostic tools, variability in diagnostic accuracy, and limited accessibility in developing regions. Regulatory hurdles and the need for skilled personnel to interpret complex diagnostic data further inhibit growth. Potential opportunities exist in the expansion of telehealth and remote diagnostic capabilities, which could democratize access to high-quality diagnostics worldwide. Moreover, partnerships between biotech firms and academic institutions could accelerate the research and development of innovative diagnostic tools.

Innovation in non-invasive diagnostic methods, such as blood-based tests or improved imaging techniques with higher sensitivity and specificity, presents a promising area for research and market growth. Fostering collaborations across the healthcare ecosystem to streamline data sharing and integrate diagnostic tools into comprehensive care pathways are crucial steps forward. Despite inherent challenges, the brain cancer diagnostics market is evolving towards a more integrated, patient-centered approach, driven by technological innovation and the continuous quest for improved clinical outcomes. Businesses should capitalize on advancements in AI and personalized medicine trends to stay competitive and drive future growth in this dynamic sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Brain Cancer Diagnostics Market

The Brain Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidence of brain cancer
    • Growth in the number of private diagnostic centers and rising public-private partnerships
  • Market Restraints
    • Heavy costs associated with diagnosis and low awareness about the diagnosis
  • Market Opportunities
    • Technological advancement in diagnostics devices
    • Development of diagnostic approaches for various cancer mutations
  • Market Challenges
    • Rising risk of high radiation exposure and stringent regulatory guidelines

Porter's Five Forces: A Strategic Tool for Navigating the Brain Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Brain Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Brain Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Brain Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Brain Cancer Diagnostics Market

A detailed market share analysis in the Brain Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Brain Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Brain Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Brain Cancer Diagnostics Market

A strategic analysis of the Brain Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Brain Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Associated Regional and University Pathologists, Inc., Becton, Dickinson and Company, Bristol Myers Squibb Co., F. Hoffmann-La Roche AG by Roche Holding AG, Fujifilm Holdings Corporation, GE Healthcare, Grail, LLC, Henry Ford Health, Hitachi, Ltd., Hologic, Inc., Illumina, Inc., Invitae Corporation, Koninklijke Philips N.V., Laboratory Corporation of America Holdings, NantOmics, NeoGenomics Laboratories, Inc., Novocure GmbH, Oncologica Limited, Quibim, S.L., Siemens Healthineers AG, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Brain Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test Type, market is studied across Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, PET Scan, and Spinal Tap.
  • Based on Brain Cancer Type, market is studied across Acoustic Neuroma, Astrocytomas, Chordomas, and Ependymomas.
  • Based on End-User, market is studied across Diagnostic Centers and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of brain cancer
      • 5.1.1.2. Growth in the number of private diagnostic centers and rising public-private partnerships
    • 5.1.2. Restraints
      • 5.1.2.1. Heavy costs associated with diagnosis and low awareness about the diagnosis
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement in diagnostics devices
      • 5.1.3.2. Development of diagnostic approaches for various cancer mutations
    • 5.1.4. Challenges
      • 5.1.4.1. Rising risk of high radiation exposure and stringent regulatory guidelines
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Brain Cancer Diagnostics Market, by Test Type

  • 6.1. Introduction
  • 6.2. Magnetic Resonance Imaging
  • 6.3. Magnetic Resonance Spectroscopy
  • 6.4. PET Scan
  • 6.5. Spinal Tap

7. Brain Cancer Diagnostics Market, by Brain Cancer Type

  • 7.1. Introduction
  • 7.2. Acoustic Neuroma
  • 7.3. Astrocytomas
  • 7.4. Chordomas
  • 7.5. Ependymomas

8. Brain Cancer Diagnostics Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic Centers
  • 8.3. Hospitals & Clinics

9. Americas Brain Cancer Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Brain Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Brain Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Associated Regional and University Pathologists, Inc.
  • 3. Becton, Dickinson and Company
  • 4. Bristol Myers Squibb Co.
  • 5. F. Hoffmann-La Roche AG by Roche Holding AG
  • 6. Fujifilm Holdings Corporation
  • 7. GE Healthcare
  • 8. Grail, LLC
  • 9. Henry Ford Health
  • 10. Hitachi, Ltd.
  • 11. Hologic, Inc.
  • 12. Illumina, Inc.
  • 13. Invitae Corporation
  • 14. Koninklijke Philips N.V.
  • 15. Laboratory Corporation of America Holdings
  • 16. NantOmics
  • 17. NeoGenomics Laboratories, Inc.
  • 18. Novocure GmbH
  • 19. Oncologica Limited
  • 20. Quibim, S.L.
  • 21. Siemens Healthineers AG
  • 22. Thermo Fisher Scientific, Inc.